Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma

被引：30
|
作者：
Vermassen, T. [1 ]
De Meulenaere, A. [1 ]
Van de Walle, M. [1 ]
Rottey, Sylvie [1 ]
机构：
[1] Ghent Univ Hosp, Dept Med Oncol, 2BII,De Pintelaan 185, B-9000 Ghent, Belgium
来源：
ACTA CLINICA BELGICA | 2017年 / 72卷 / 01期
关键词：
Renal cell carcinoma; surgery; systemic therapy; CHRONIC KIDNEY-DISEASE; BLIND PHASE-III; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; CYTOREDUCTIVE NEPHRECTOMY; RADIOFREQUENCY ABLATION; SURGICAL-MANAGEMENT; OPEN-LABEL; SURVIVAL; SUNITINIB;
D O I：
10.1080/17843286.2016.1193269
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Renal cell carcinoma (RCC) accounts for 2.4% of all malignancies worldwide diagnosed with 338,000 estimated new cases globally in 2012. In the last decade, the therapeutic landscape for RCC patients has changed tremendously. In this review, we will summarize the treatment options currently available for clear-cell localized, advanced and metastatic RCC (mRCC); as stated in the ESMO clinical practice guidelines, the EAU guidelines and the NCCN guidelines. Furthermore, we will discuss the recommended therapies in patients diagnosed with non-clear cell tumours.
引用
收藏
页码：12 / 18
页数：7
相关论文
共 50 条
  • [1] Non-clear cell renal cell carcinoma
    Ahrens, Marit
    Bergmann, Lothar
    UROLOGIE, 2024, 63 (12): : 1240 - 1245
  • [2] Non-Clear Cell Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 8 - 10
  • [3] Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma
    Heng, Daniel Y. C.
    Bukowski, Ronald M.
    ONCOLOGY REVIEWS, 2007, 1 (03) : 170 - 176
  • [4] Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
    Xu K.Y.
    Wu S.
    Biomarker Research, 3 (1)
  • [5] Metastatic non-clear cell renal cell carcinoma: current therapeutic options
    Schrader, Andres J.
    Olbert, Peter J.
    Hegele, Axel
    Varga, Zoltan
    Hofmann, Rainer
    BJU INTERNATIONAL, 2008, 101 (11) : 1343 - 1345
  • [6] Updates in the Systemic Therapy Options for Clear Cell and Non-Clear Cell Renal Cell Carcinoma
    Spiess, Philippe E.
    Johnstone, Peter A. S.
    Jonasch, Eric
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (5.5):
  • [7] The role of immunotherapy in non-clear cell renal cell carcinoma
    Climent, Carla
    Soriano, Sandra
    Bonfill, Teresa
    Lopez, Natalia
    Rodriguez, Marta
    Sierra, Marina
    Andreu, Pablo
    Fragio, Monica
    Busquets, Mireia
    Carrasco, Alicia
    Cano, Ona
    Segui, Miguel-Angel
    Gallardo, Enrique
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] Renal cell carcinoma: The effect of targeted therapies on clear cell and non-clear cell histologies.
    Marascio, Joseph A.
    Rabatic, Bryan M.
    Zaenger, David
    Madden, Nicholas A.
    Marchan, Edward M.
    McDermott, David
    Misiura, Anne Kathryn
    Shaaban, Sherif
    Dasher, Byron G.
    Huang, Ke
    Pishgou, Mahboubeh
    Martin, William D.
    Aletan, Maryam
    Howington, Jed W.
    Albasheer, Ahmad M.
    Amoush, Ahmad
    Stewart, John G.
    Kong, Feng-Ming
    Ferguson, Catherine L.
    Mourad, Waleed F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma
    Naik, Priyanka
    Dudipala, Harshitha
    Chen, Yu-Wei
    Rose, Brent
    Bagrodia, Aditya
    Mckay, Rana R.
    THERAPEUTIC ADVANCES IN UROLOGY, 2024, 16
  • [10] Targeted therapies for non-clear renal cell carcinoma
    Eric A. Singer
    Gennady Bratslavsky
    W. Marston Linehan
    Ramaprasad Srinivasan
    Targeted Oncology, 2010, 5 : 119 - 129
12345